加载中
NASDAQHealthcareBiotechnology
最新数据
US$4.5296
−US$0.1604 · -3.42%
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
常规交易时段
US$4.5296
−US$0.1604 · -3.42%
盘中时间采用ET。市场数据可能有所延迟。
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
日内区间
当前US$4.5296
52周区间
当前US$4.5296
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
37
偏贵
情绪
51
多空交织
风险
47
风险偏高
动量
61
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
日内区间
当前US$4.5296
52周区间
当前US$4.5296
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI563.59万0.00%2.3万亿 USD0.03%US$380.82-0.20%
Vanguard U.S. Momentum Factor ETFVFMO242.2万0.12%19亿 USD0.13%US$225.95-0.77%
iShares Russell 2000 ETFIWM225.9万0.00%787.4亿 USD0.19%US$276.26-0.59%
Vanguard Extended Market ETFVXF100.9万0.00%954亿 USD0.05%US$231.93-0.68%
iShares Biotechnology ETFIBB97.12万0.01%108.2亿 USD0.44%US$201.82-1.19%
iShares Russell 2000 Growth ETFIWO80.9万0.01%139.17亿 USD0.24%US$350.8-0.82%
Vanguard Russell 2000 ETFVTWO63.8万0.00%180亿 USD0.06%US$111.57-0.62%
Schwab U.S. Small-Cap ETFSCHA47.57万0.00%217.13亿 USD0.03%US$32.465-0.60%Vanguard Morningstar Total Stock Market ETFVTIVanguard U.S. Momentum Factor ETFVFMOiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
